Awesome attorneys!
Glenn Rice
7 years ago
Zinbryta Lawyers Parker Waichman LLP Warn About The Potential For Brain Injury Biogen and AbbVie, the makers of Zinbryta (daclizumab), have voluntarily removed the product from the marketplace due to recent developments that indicate taking the drug could cause serious brain inflammation. The companies cite the variance between the risk of suffering an additional […]
Biogen and AbbVie, the makers of Zinbryta (daclizumab), have voluntarily removed the product from the marketplace due to recent developments that indicate taking the drug could cause serious brain inflammation. The companies cite the variance between the risk of suffering an additional illness or injury from taking the drug and the benefit the medication provides to patients. In this situation, the risks far outweigh the benefits conferred to patients. Consequently, Biogen and AbbVie determined that market withdrawal is the best option. You or your loved one who take Zinbryta must be aware that continued use of the drug may lead to severe adverse health consequences. Therefore, you must contact your physician immediately.
The U.S. Food and Drug Administration (FDA) announced that consumers of Zinbryta must continue taking the drug until receiving further orders from their physician. According to the FDA, doctors must be cautious about transitioning their patients from Zinbryta and starting them on another treatment regimen. The manufacturers of Zinbryta and the FDA announced that no doctors would prescribe the drug to new patients and no studies of the drug will commence. However, Zinbryta will be available on the market until April 30, 2018, to accommodate patients who require their medication until they can switch to an alternative treatment for advice on how to proceed.
Parker Waichman LLP is a national law firm with a sophisticated plaintiffs’ law practice that emphasizes a small firm feel. Parker Waichman LLP wants their clients to know that their case is a priority for them. Do not be fooled into believing that Parker Waichman LLP’s Zinbryta defect attorneys are small-town lawyers who do not have what it takes to join the battle with large drug makers like Biogen and AbbVie by the individualized attention each client receives from their drug defect lawyer with Parker Waichman LLP. On the contrary, Parker Waichman LLP’s drug defect attorneys have successfully prosecuted numerous claims against some of the largest medical manufacturers in business in the U.S. With a track record of recovering over $2 billion for their clients. You can trust Parker Waichman LLP’s medical product injury lawyers to relentlessly pursue justice for you and your loved ones.
Biogen and AbbVie manufactured Zinbryta to help patients relieve some of the symptoms of relapsing multiple sclerosis. The FDA admits that Zinbryta was a risky drug, notwithstanding the fact that the FDA approved the medication for consumer use. As discussed below, Zinbryta has the potential to cause life-threatening liver problems. However, the FDA limited the availability of Zinbryta to patients whose medical history indicates that they have at least two failed attempts at alternative therapies.
The FDA and other agencies like the European Medicines Agency recognize that Zinbryta consumption may result in irreversible and possibly lethal brain inflammation conditions. Consequently, both agencies issued warnings to Zinbryta users to discontinue taking the drug and consult their doctor to find an alternative therapy. The restrictions come after 12 people developed swelling of the brain called encephalitis or meningoencephalitis linked to Zinbryta use. The European Medicines Agency reported that it knew of a few cases which resulted in death from taking Zinbryta. Additionally, the other people who experienced brain swelling did not have a full recovery even when treated with powerful drugs to treat the swelling like corticosteroids.
Encephalitis is a terrible medical condition. Physical indications of encephalitis include a headache, which could be severe, neck ache, fever, weakness, and fatigue. The most severe cases involving encephalitis include symptoms of:
Treatment for encephalitis involves administering medications that reduce swelling like corticosteroids. Additionally, pain relievers will be given to ease the pain from headaches and muscle aches. Anti-seizure medication might also be prescribed. Other treatments will vary depending on the severity of the swelling, the age of the patient, and overall health of the patient.
The patient might require various therapies to regain strength. Therefore, the treating physician might prescribe a course of physical therapy, speech therapy, occupational therapy, and psychological help depending on the needs of the particular patient. Encephalitis can cause permanent brain damage if the swelling does not subside.
The FDA did not allow Zinbryta onto the open market without requiring Black Box Warnings when the agency first approved the drug for retail sale. The FDA mandated that Zinbryta’s packaging must have the conspicuous Black Box Warning communicating the potential damage relapsing multiple sclerosis patients could experience in his or her liver by taking Zinbryta. In fact, a drug safety update from the United Kingdom suggests that people suffering from Hepatitis B and C must be closely monitored for complications while taking Zinbryta.
The European Medicines Agency strongly cautioned doctors and patients about the potential damage Zinbryta could cause a patient. The Agency warned that fatal liver conditions could occur while taking Zinbryta and could last for six months after the patients stop taking the drug. The European Medicines Agency could not determine a pattern of disease and therefore defined it as “unpredictable.” Additionally, accompanying that warning was a declaration that Zinbryta might cause autoimmune hepatitis, hepatitis, or jaundice. One or more of those liver complications arose in 1.7% of all Zinbryta users in clinical trials conducted in the U.K.
Contact your physician immediately and discuss alternatives to Zinbryta. It is vital to your health that you pay very close attention to any change in your overall well-being on a day-to-day basis. You must consult your physician if you notice that you do not feel well. Early intervention might prevent encephalitis and liver damage. Your physician will know what therapies to start you on and what steps to take to prevent additional damage from occurring.
You must contact an experienced, knowledgeable, and skilled drug defect lawyer to represent your legal interests if you or a family member experiences complications due to Zinbryta. Even though Zinbryta’s manufacturers recalled the drug, patients who experience severe side effects including encephalitis and other complications may be eligible for a substantial financial award.
You or your loved one may need to pursue your legal remedies and seek compensation for your damages so that you can manage the financial burden associated with caring for a person recovering from encephalitis. Brain damage caused by encephalitis could last a lifetime. It is essential that you and your family explore your legal options and file a claim if you determine that be in your best interest.
The amount of time you have to file a legal claim for damages caused by Zinbryta is limited. Your state’s statute of limitations will determine how long you have to file a claim in court. You must not delay in contacting a Zinbryta lawyer with Parker Waichman LLP. Delaying may irrevocably ruin your chances to recover any compensation for your Zinbryta loss.
Parker Waichman LLP’s Zinbryta lawyers have the skill, knowledge, and experience upon which you and your family can rely to maximize your opportunity to recover a substantial economic award. Contact Parker Waichman LLP today at 1-800-YOURLAWYER (1-800-968-7529) or use our contact form to learn more about your Zinbryta legal claim.